TY - JOUR
T1 - PET cell tracking using 18 F-FLT is not limited by local reuptake of free radiotracer
AU - Macaskill, Mark G.
AU - Tavares, Adriana S.
AU - Wu, Junxi
AU - Lucatelli, Christophe
AU - Mountford, Joanne C.
AU - Baker, Andrew H.
AU - Newby, David E.
AU - Hadoke, Patrick W.F.
PY - 2017/3/13
Y1 - 2017/3/13
N2 - Assessing the retention of cell therapies following implantation is vital and often achieved by labelling cells with 2′-[ 18 F]-fluoro-2′-deoxy-D-glucose (18 F-FDG). However, this approach is limited by local retention of cell-effluxed radiotracer. Here, in a preclinical model of critical limb ischemia, we assessed a novel method of cell tracking using 3′-deoxy-3′-L-[ 18 F]-fluorothymidine (18 F-FLT); a clinically available radiotracer which we hypothesise will result in minimal local radiotracer reuptake and allow a more accurate estimation of cell retention. Human endothelial cells (HUVECs) were incubated with 18 F-FDG or 18 F-FLT and cell characteristics were evaluated. Dynamic positron emission tomography (PET) images were acquired post-injection of free 18 F-FDG/ 18 F-FLT or 18 F-FDG/ 18 F-FLT-labelled HUVECs, following the surgical induction of mouse hind-limb ischemia. In vitro, radiotracer incorporation and efflux was similar with no effect on cell viability, function or proliferation under optimised conditions (5 MBq/mL, 60 min). Injection of free radiotracer demonstrated a faster clearance of 18 F-FLT from the injection site vs. 18 F-FDG (p ≤ 0.001), indicating local cellular uptake. Using 18 F-FLT-labelling, estimation of HUVEC retention within the engraftment site 4 hr post-administration was 24.5 ± 3.2%. PET cell tracking using 18 F-FLT labelling is an improved approach vs. 18 F-FDG as it is not susceptible to local host cell reuptake, resulting in a more accurate estimation of cell retention.
AB - Assessing the retention of cell therapies following implantation is vital and often achieved by labelling cells with 2′-[ 18 F]-fluoro-2′-deoxy-D-glucose (18 F-FDG). However, this approach is limited by local retention of cell-effluxed radiotracer. Here, in a preclinical model of critical limb ischemia, we assessed a novel method of cell tracking using 3′-deoxy-3′-L-[ 18 F]-fluorothymidine (18 F-FLT); a clinically available radiotracer which we hypothesise will result in minimal local radiotracer reuptake and allow a more accurate estimation of cell retention. Human endothelial cells (HUVECs) were incubated with 18 F-FDG or 18 F-FLT and cell characteristics were evaluated. Dynamic positron emission tomography (PET) images were acquired post-injection of free 18 F-FDG/ 18 F-FLT or 18 F-FDG/ 18 F-FLT-labelled HUVECs, following the surgical induction of mouse hind-limb ischemia. In vitro, radiotracer incorporation and efflux was similar with no effect on cell viability, function or proliferation under optimised conditions (5 MBq/mL, 60 min). Injection of free radiotracer demonstrated a faster clearance of 18 F-FLT from the injection site vs. 18 F-FDG (p ≤ 0.001), indicating local cellular uptake. Using 18 F-FLT-labelling, estimation of HUVEC retention within the engraftment site 4 hr post-administration was 24.5 ± 3.2%. PET cell tracking using 18 F-FLT labelling is an improved approach vs. 18 F-FDG as it is not susceptible to local host cell reuptake, resulting in a more accurate estimation of cell retention.
KW - cell therapy
KW - cardiovascular disease
KW - positron emission tomography
UR - http://www.scopus.com/inward/record.url?scp=85015255581&partnerID=8YFLogxK
U2 - 10.1038/srep44233
DO - 10.1038/srep44233
M3 - Article
C2 - 28287126
AN - SCOPUS:85015255581
VL - 7
JO - Scientific Reports
JF - Scientific Reports
SN - 2045-2322
M1 - 44233
ER -